米拉贝格伦,一种选择性β3-上腺素受体激动剂,作为一种潜在的抗肥胖药物
Anna Maria Dąbrowska1,2, Jarosław Dudka1
1Department of Toxicology, Medical University of Lublin, Jaczewskiego Street 8b, 20-090 Lublin, Poland.
Journal of clinical medicine
|November 14, 2023
概括
米拉贝格伦激活棕色和色脂肪细胞燃烧卡路里,但需要更多的研究来证实显著的减肥和肥胖患者的长期安全性. 未来的研究需要更大的小组和更长的时间.
科学领域:
- 代谢研究的研究.
- 脂肪组织生物学 脂肪组织生物学
- 药理学 药理学 是一个学科.
背景情况:
- 肥胖是一个全球性的健康危机.
- 棕色和色脂肪组织产生热量,可能有助于体重控制.
- 米拉贝格伦是一种选择性β3-上腺素受体激动剂,研究其对脂肪组织的影响.
研究的目的:
- 评估mirabegron作为治疗肥胖症的疗效和安全性.
- 探索mirabegron在刺激棕色和色脂肪组织中的作用.
- 评估与mirabegron治疗相关的减肥潜力.
主要方法:
- 对Mirabegron的作用进行的动物和人类研究的综述.
- 分析mirabegron对脂肪组织激活和能量消耗的影响.
- 考虑剂量,持续时间和心血管安全.
主要成果:
- 动物研究表明,mirabegron可以改善肥胖.
- 人类研究表明,mirabegron激活脂肪组织,但尚未证明显著的体重减轻.
- 对人类有效的高剂量可能会产生心血管方面的副作用.
结论:
- 米拉贝格朗通过刺激脂肪代谢,显示出对治疗肥胖的潜力.
- 需要对更大的队列进行进一步的长期试验,以确认有效性和安全性.
- 在较长时间内研究较低剂量可能是有益的.
相关概念视频
Antidepressant Drugs: MAOIs and Other Agents
252
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
252
Drugs for Treatment of Diarrhea-Predominant IBS
186
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
186
Drugs for Treatment of Constipation-Predominant IBS
181
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
181
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
270
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
270
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
183
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
183
Glucagon-like Receptor Agonists
332
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
332


